Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 2, 2011, Pages 196-214

  Miao, Xiaoqing ^a   Sun, Changshan ^a   Jiang, Tongying ^a   Zheng, Li ^a   Wang, Tianyi ^a   Wang, Siling ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; NANOCRYSTAL; NITROGEN; STABILIZING AGENT; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DOG; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STRUCTURE; DRY POWDER; FEMALE; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR IMAGING; MOLECULAR SIZE; NONHUMAN; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; STRUCTURE ANALYSIS; SURFACE PROPERTY; TABLET POROSITY; X RAY DIFFRACTION; X RAY PHOTOELECTRON SPECTROSCOPY;

EID: 79959317121     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3pw2w     Document Type: Article

References (35)

1. Patravale, V.B., Date, A.A., Kulkarni, R.M. Nanosuspensions: a promising drug delivery strategy. J. Pharm. Pharmacol, 2004; 56: 827-840.
2. Rabinow BE. Nanosuspensions in drug delivery. Nature rev Drug Disc, 2004; 3: 785-796.
3. A.A. Noyes, W.R. Whitney. The rate of solution of solid substances in their own solutions, J. Am. Chem. Soc, 1897; 19: 930-934.
4. Dressmann JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 2000; 11: 73-80.
5. Kesisoglou, F., Panmai, S., Wu, Y., Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev, 2007; 59: 631-644.
6. Xiong, R., Lu,W., Li, J.,Wang, P., Xu, R., Chen, T., Preparation and characterization of intravenously injectable nimodipine nanosuspension, Int. J. Pharm. 2008; 350:338-343.
7. Krause, K., Müller, R.H. Production and characterization of highly concentrated nanosuspensions by high pressure homogenization. Int. J. Pharm, 2001; 214: 21-24.
8. Guo, R., Zhang, L.Y., Jiang, Zh.P., Cao, Y., Ding, Y., Jiang, X.Q., Synthesis of alginic acid-poly[2-(diethylamino) ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system. Biomacromolecules, 2007; 8: 843-850.
9. Muller RH, Jacobs C, Kayser O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 2001; 47:3-19.
10. Van Eerdenbrugh, B., Froyen, L.,Martens, J.A., Blaton, N., Augustijns, P., Brewster,M.,Van den Mooter, G., Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm, 2007; 338: 198-206.
11. Van Eerdenbrugh, B., Van den Mooter, G., Augustijns, P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int. J. Pharm, 2008; 364: 64-75.
12. U. Hayato, T. Toshio, K. Yukio, H. Hiroyoshi, Biochem. Pharmacol, 1984; 33: 3339.
13. Y. Kimura, T. Tani, T. Kanbe, K. Watanabe. Arzneimittel forschung, 1985; 35: 1144.
14. E.M. Sorkin, A. Markham, Drugs Aging, 1999; 14: 63.
15. G.L. Amidon, H. Lennernas, V.P. Shah, J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res, 1995; 12: 413-420.
16. T. Shimizu, T. Osumi, K. Niimi, K. Nakagawa, Physico-chemical properties and stability of cilostazol, Arzneimittelforschung 1985, 35: 1117-1123.
17. H. Toyobuku, I. Tamai, K. Ueno, A. Tsuji, Limited influence of Pglycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug, J. Pharm. Sci. 2003; 92: 2249-2259.
18. S.L. Bramer, W.P. Forbes., Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics, Clin. Pharmacokinet, 1999; 37 (Suppl 2): 13-23.
19. Jun-ichi Jinno, Naoki Kamada. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release, 2006; 111: 56 - 64.
20. Jun-ichi Jinno, Naoki Kamada. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J. Control. Release, 2008; 130: 29-37.
21. Samir G. Patel and Sadhana J. Rajput. Enhancement of Oral Bioavailability of Cilostazol by Forming its Inclusion Complexes. AAPS Pharm SciTech, 2009;Vol. 10, No. 2, June 2009.
22. Min-Soo Kim, Sibeum Lee, Jeong-Sook Park, Jong-Soo Woo, Sung-Joo Hwang. Micronization of cilostazol using supercritical antisolvent (SAS) process:Effect of process parameters. Powder Technology, 2007; 177: 64-70.
23. K. Chen, X. Zhang, J. Pan, W. Yin, J. Cryst. Growth 274 (2005) 226.
24. G.W. Stowell, R.R. White, US Patent. 2003:6531603.
25. Andrej Dolenc, Julijana Kristl, Sa? sa Baumgartner, Odon Planin? sek. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm, 2009; 376:204-212.
26. Hai Xia Zhang, Jie XinWang, Zhi Bing Zhang, Yuan Le, Zhi Gang Shen, Jian Feng Chen. Micronization of atorvastatin calcium by antisolvent precipitation process. Int. J. Pharm, 2009; IJP-10540; No. of Pages8.
27. G.W. Stowell, R.J. Behme, S.M. Denton, I. Pfeiffer, F.D. Sancilio, L.B. Whittall, R.R. Whittle. J. Pharm. Sci, 2002; 91: 2481.
28. M.E. Morales, M.A. Ruiz, I.Oliva, M.Oliva, V. Gallardo. Chemical characterization with XPS of the surface of polymer microparticles loaded with morphine. Int. J. Pharm, 2007; 333: 162-166.
29. Piera Di Martino, Mara Scoppa, Etienne Joiris, Giovanni F. Palmieri, Cyrille Andres, Yvette Pourcelot, Sante Martelli. The spray drying of acetazolamide as method to modify crystal properties and to improve compression behaviour. Int. J. Pharm, 2001; 213: 209-221.
30. Paradkar AR, Pawar AP, Chordiya JK, Patil VB, Ketkar AR. Spherical crystallization of celecoxib. Drug Dev Ind Pharm, 2002; Vol. 28, No. 10: pp.1213-1220.
31. Dengning Xia, Peng Quan, Hongze Piao, Hongyu Piao, Shaoping Sun. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur. J. Pharm. Sci, 2010; 40: 325-334.
32. Yinghui Liu, Changshan Sun, Yanru Hao, Tongying Jiang, Li Zheng, Siling Wang. Mechanism of Dissolution Enhancement and Bioavailability of Poorly Water Soluble Celecoxib by Preparing Stable Amorphous Nanoparticles. J Pharm Pharmaceut Sci, 2010;13(4):589 - 606.
33. Wong S M, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles.Int J Pharm, 2006; 317: 61-68.
34. Anne Zimmermann, Anna Millqvist-Fureby, Michiel Ringkjøbing Elema, Tue Hansen, Anette Müllertz, Lars Hovgaard., Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: Effects on physicochemical properties. Eur. J. Pharm. Biopharmaceutics, 2009;71: 109-116.
35. D. Giron. J. Therm. Anal. Calorim. 2002; 68, p. 353.